Share: Facebook Twitter LinkedIn
Activity Provided By:

Physicians’ Education Resource®, LLC

Clinical Consultations™: Expert Perspectives in Choroideremia – Analyzing the Potential Impact of Gene Therapy

Access Activity

Overview / Abstract:

Target Audience
This online educational activity is directed toward retinal specialists and ophthalmologists. Other healthcare providers involved of the care of patients suffering from CHM are also invited to participate.

Activity Overview
Choroideremia (CHM) is a rare, X-linked, inherited retinal disorder characterized by progressive vision loss, usually beginning with night-blindness, followed by peripheral vision loss, and eventually leading to complete loss of sight. The disease is associated with mutations in the CHM gene that lead to degeneration of the photoreceptors, retinal pigment epithelium, and choroid. Although there is no cure, advances in CHM pathogenetics have had significant clinical implications. Clinical gene therapy trials in patients with CHM have demonstrated the potential for slowing or even stopping the degeneration characteristic of this disease. As CHM gene therapy approaches regulatory approval, clinicians need to remain up-to-date with these developments so they can recommend appropriate treatments as they become available.

In this on-demand, online CME activity, two faculty experts in choroideremia and gene therapy discuss the pathophysiology, diagnosis, and emerging treatments for CHM. In their discussion, they share their experiences in caring for patients with choroideremia, giving learners practical insights into this rare disease. Their firsthand experience with clinical trials sheds new light on the potential role of emerging gene therapies in the treatment of this disease.

Learning Objectives
Upon completion of this activity, you should be better able to:

Discuss the role of the CHM gene in the pathophysiology of choroideremia
Identify the clinical features of choroideremia that differentiate it from similar retinal diseases
Evaluate the clinical trial data for current and emerging gene therapies in the treatment of choroideremia

Expiration

Mar 22, 2022

Discipline(s)

Physician CME

Format

Online

Credits / Hours

1.5

Accreditation

ACCME

Presenters / Authors / Faculty

M. Dominik Fischer, MD, PhD, FEBO
Byron L. Lam, MD

Sponsors / Supporters / Grant Providers

Biogen

Keywords / Search Terms

Relias LLC Relias, Free CME, Choroideremia, Gene Therapy Free CE CME

Access Activity

CORE Higher Education Group, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps.CORE Higher Education Group, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map